First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

(2013) D W Miles et al.   BRITISH JOURNAL OF CANCER

Targeting triple-negative breast cancer: optimising therapeutic outcomes

(2012) K. Gelmon et al.   ANNALS OF ONCOLOGY

Progress Against Solid Tumors in Danger: The Metastatic Breast Cancer Example

(2012) Javier Cortés et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial

(2012) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Avastin Saga Reveals Debate Over Clinical Trial Endpoints

(2012) S. P. Sharma   JNCI-Journal of the National Cancer Institute

Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence

(2012) José R. Rossari et al.   Journal of Oncology

Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis

(2011) J. Cortes et al.   ANNALS OF ONCOLOGY

Treatment-Related Mortality With Bevacizumab in Cancer Patients

(2011) Vishal Ranpura et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Survival Is Not a Good Outcome for Randomized Trials With Effective Subsequent Therapies

(2011) Marc Buyse et al.   JOURNAL OF CLINICAL ONCOLOGY

RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

(2011) Adam M. Brufsky et al.   JOURNAL OF CLINICAL ONCOLOGY

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

(2011) Nicholas J. Robert et al.   JOURNAL OF CLINICAL ONCOLOGY

Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab

(2011) Toni K. Choueiri et al.   JOURNAL OF CLINICAL ONCOLOGY

Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials

(2011) Federica Cuppone et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

(2011) Miguel Martin et al.   LANCET ONCOLOGY

First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients

(2010) I. E. Smith et al.   ANNALS OF ONCOLOGY

Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials

(2010) A. Valachis et al.   BREAST CANCER RESEARCH AND TREATMENT

Overall survival in metastatic breast cancer: always our quest but not necessarily a primary endpoint

(2010) Nicholas J. Robert   BREAST CANCER RESEARCH AND TREATMENT

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

(2010) David W. Miles et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab for salvage treatment of metastatic breast cancer: a systemic review and meta-analysis of randomized controlled trials

(2009) Jae-Bok Lee et al.   INVESTIGATIONAL NEW DRUGS